7ACC2: Carboxycoumarin MCT1 Inhibitor for Cancer Metabolism Research

Executive Summary: 7ACC2 is a carboxycoumarin derivative and potent inhibitor of monocarboxylate transporter 1 (MCT1), exhibiting an IC50 of ~10 nM for lactate uptake in SiHa human cervical carcinoma cells (APExBIO product page). It also inhibits mitochondrial pyruvate transport, disrupting both extracellular lactate and intracellular pyruvate flux. In preclinical models, 7ACC2 delays tumor growth and enhances radiosensitivity by targeting metabolic vulnerabilities in cancer cells (Xiao et al., 2024). The compound is insoluble in water and ethanol but dissolves in DMSO at concentrations ≥47.5 mg/mL and should be stored at -20°C. 7ACC2 serves as a dual-action research tool for dissecting cancer metabolism and immunometabolic crosstalk, with growing utility in translational oncology (internal ref).

Biological Rationale

The metabolic reprogramming of cancer cells involves increased reliance on glycolysis, leading to excessive lactate production and export. The monocarboxylate transporter (MCT) family, particularly MCT1 (SLC16A1) and MCT4 (SLC16A3), enables proton-linked transmembrane transport of short-chain monocarboxylates such as lactate and pyruvate (Xiao et al., 2024). MCT1 is highly expressed in many tumor cells and is critical for lactate uptake into oxidative cancer cells, supporting their metabolic flexibility. Inhibition of MCT1 is hypothesized to limit metabolic crosstalk in the tumor microenvironment, restricting both cancer cell growth and immunosuppressive signaling mediated by tumor-associated macrophages (TAMs). Recent evidence identifies lactate and related metabolite transport as key modulators of the immunometabolic landscape, impacting T cell infiltration and macrophage polarization (Disrupting Cancer’s Metabolic Axis).

Mechanism of Action of 7ACC2

7ACC2 is a synthetic carboxycoumarin derivative developed to selectively inhibit MCT1. It binds to the transporter and blocks the transmembrane movement of lactate, with an IC50 of ~10 nM for lactate uptake inhibition in SiHa cells at 37°C (APExBIO). 7ACC2 also inhibits mitochondrial pyruvate transport, interfering with pyruvate import into the mitochondrial matrix and thereby disrupting the TCA cycle and oxidative phosphorylation in tumor cells. This dual inhibition limits both the influx of extracellular lactate and mitochondrial pyruvate utilization, resulting in metabolic stress and reduced tumor cell proliferation (7ACC2: Carboxycoumarin MCT1 Inhibitor).

Mechanistically, 7ACC2’s blockade of lactate uptake deprives oxidative tumor cells of a key carbon source, while pyruvate transport inhibition further impairs energy production and biosynthetic pathways. This combined action can sensitize tumors to radiotherapy, as shown in SiHa xenograft models.

Evidence & Benchmarks

• 7ACC2 inhibits MCT1-mediated lactate uptake in SiHa human cervical carcinoma cells with an IC50 of approximately 10 nM (APExBIO, product page).
• In SiHa mouse xenograft models, 7ACC2 treatment delayed tumor growth, especially when combined with radiotherapy (Xiao et al., 2024, DOI).
• 7ACC2 is insoluble in water and ethanol but is soluble in DMSO at ≥47.5 mg/mL; recommended storage is at -20°C (APExBIO, product page).
• MCT1 and MCT4 are predominantly overexpressed in cancer cells and correlate with enhanced lactate flux and tumor progression (Xiao et al., 2024, DOI).
• Recent studies highlight the role of lactate and monocarboxylate transport in modulating immunosuppressive macrophage phenotypes within the tumor microenvironment (Targeting Lactate Flux and Immunometabolic Checkpoints).

Applications, Limits & Misconceptions

• 7ACC2 is used for dissecting cancer cell metabolic dependencies, especially for studies involving lactate and pyruvate flux.
• It enables interrogation of metabolic crosstalk between cancer cells and immune cells, such as TAMs, by modulating the tumor microenvironment.
• 7ACC2 has been applied in radiosensitization studies, demonstrating enhanced efficacy when paired with standard radiotherapy in preclinical models (Xiao et al., 2024).
• Its dual action on both MCT1 and mitochondrial pyruvate transport sets it apart from single-target MCT inhibitors (Unlocking Metabolic and Immunometabolic Vulnerabilities).

Common Pitfalls or Misconceptions

• 7ACC2 is not a pan-MCT inhibitor; it does not significantly inhibit MCT2, MCT3, or MCT4 at relevant concentrations.
• It is not suitable for in vivo applications requiring aqueous solubility without DMSO.
• 7ACC2 is not a diagnostic or therapeutic agent and is for research use only.
• It may not recapitulate metabolic effects in non-tumor or primary cell systems lacking high MCT1 expression.
• Long-term storage of 7ACC2 solutions is not recommended due to potential degradation.

Workflow Integration & Parameters

7ACC2 (SKU: B4868) is supplied by APExBIO for scientific research purposes. It is shipped on blue ice and requires -20°C storage. For in vitro assays, dissolve 7ACC2 in DMSO to a stock concentration of 47.5 mg/mL or higher. Working concentrations should be optimized between 1–100 nM for lactate uptake inhibition, depending on cell type and assay conditions. Avoid using water or ethanol as solvents due to insolubility. Long-term solution storage is discouraged; prepare fresh aliquots for each experiment (APExBIO product page).

7ACC2 can be integrated into metabolic flux assays, radiotherapy sensitization protocols, or studies examining immunometabolic reprogramming. For further guidance on integrating 7ACC2 into advanced cancer metabolism workflows, see Redefining Cancer Metabolism, which this article updates by providing the latest data on 7ACC2’s dual mechanism of action and integration with immunometabolic checkpoint research.

Conclusion & Outlook

7ACC2 is a validated, dual-function carboxycoumarin inhibitor of MCT1 and mitochondrial pyruvate transport, offering a robust tool for dissecting metabolic and immunometabolic vulnerabilities in cancer. Its high potency (IC50 ~10 nM for MCT1 inhibition), combined action, and well-characterized physicochemical properties make it suitable for translational research in oncology. Ongoing studies are leveraging 7ACC2 to unravel the links between cancer metabolism, macrophage polarization, and immune escape. For comprehensive technical details or ordering, refer to the 7ACC2 product page by APExBIO.